0001725160-21-000163.txt : 20210706
0001725160-21-000163.hdr.sgml : 20210706
20210706200108
ACCESSION NUMBER: 0001725160-21-000163
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210701
FILED AS OF DATE: 20210706
DATE AS OF CHANGE: 20210706
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Epperly Melissa B,
CENTRAL INDEX KEY: 0001807359
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39263
FILM NUMBER: 211075920
MAIL ADDRESS:
STREET 1: C/O ZENTALIS PHARMACEUTICALS, INC.
STREET 2: 530 SEVENTH AVENUE, SUITE 2201
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001725160
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 530 SEVENTH AVENUE, SUITE 2201
CITY: NEW YORK
STATE: NY
ZIP: 10018
BUSINESS PHONE: (212) 433-3791
MAIL ADDRESS:
STREET 1: 530 SEVENTH AVENUE, SUITE 2201
CITY: NEW YORK
STATE: NY
ZIP: 10018
FORMER COMPANY:
FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20200107
FORMER COMPANY:
FORMER CONFORMED NAME: Zeno Pharma, LLC
DATE OF NAME CHANGE: 20171212
4
1
wf-form4_162561605028744.xml
FORM 4
X0306
4
2021-07-01
0
0001725160
Zentalis Pharmaceuticals, Inc.
ZNTL
0001807359
Epperly Melissa B,
C/O ZENTALIS PHARMACEUTICALS, INC.
530 SEVENTH AVENUE, SUITE 2201
NEW YORK
NY
10018
0
1
0
0
Chief Financial Officer
Common Stock
2021-07-01
4
S
0
700
50.1043
D
259457
D
Common Stock
2021-07-01
4
S
0
1378
51.1461
D
258079
D
Common Stock
2021-07-01
4
S
0
805
52.0062
D
257274
D
Common Stock
2021-07-01
4
S
0
200
53.185
D
257074
D
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.68 to $50.58. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.71 to $51.57. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.83 to $52.39. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.15 to $53.22. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
By: /s/ Melissa B. Epperly
2021-07-06